Over 40.1 million Americans — roughly 12% of the US population — have diabetes, a chronic condition characterized by ...

UCSF research led to the first type 1 diabetes immunotherapy. Now, scientists are using stem cells and Tregs to find a ...

Obesity therapeutics now represent ~$98B and 4.6% share, climbing to the fourth-largest category, with ~190 pipeline assets ...

U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a ...

Diabetes affects more than 40 million people in the United States, according to the American Diabetes Association. For many, ...

Diabetes is very common. The Centers for Disease Control and Prevention (CDC) notes that 38.4 million people in the United States are currently living with diabetes. That’s 11.6 percent of the ...

Resmetirom effectively resolves MASH and improves fibrosis, independent of GLP-1 or SGLT2 inhibitor use, in patients with T2DM. Achieving ≥5% weight loss enhances resmetirom's effects on MASH ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Most fat stores energy; the body's brown fat does the opposite. Unlike the white fat that accumulates just under our skin, ...

Diabetes is associated with a lower incidence of uterine fibroids in midlife women receiving diabetes treatment, especially metformin. The association between diabetes and the risk for uterine ...

Treatment-induced neuropathy of diabetes (TIND) is a rare but potentially painful complication of diabetes caused by high blood sugar and nerve damage. Treatment-induced neuropathy of diabetes (TIND) ...

Researchers found that certain immune cells, genes, and the drug metformin may help keep HIV dormant after treatment stops, ...